Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCIG vs OMT for Dyskinesia in Advanced Parkinson's Disease
NCT02799381Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc.. Started Feb 2017; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02799381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799381.